دورية أكاديمية
Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.
| العنوان: | Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. |
|---|---|
| المؤلفون: | Awada A; Medical Oncology Clinic, Institut Jules Bordet-Université libre de Bruxelles, Brussels, Belgium. ahmad.awada@bordet.be, Vandone AM, Aftimos P |
| المصدر: | Current opinion in oncology [Curr Opin Oncol] 2012 May; Vol. 24 (3), pp. 297-304. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9007265 Publication Model: Print Cited Medium: Internet ISSN: 1531-703X (Electronic) Linking ISSN: 10408746 NLM ISO Abbreviation: Curr Opin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Philadelphia, PA : Lippincott Williams & Wilkins Original Publication: Philadelphia, PA : Current Science, c1989- |
| مواضيع طبية MeSH: | Precision Medicine*, Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*pathology , Gastrointestinal Stromal Tumors/*pathology, Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; Female ; Gastrointestinal Stromal Tumors/genetics ; Gastrointestinal Stromal Tumors/therapy ; Gene Expression Profiling ; Humans ; Male ; Pathology, Molecular/trends |
| مستخلص: | Purpose of Review: In recent years, there has been a paradigm shift in the diagnosis as well as the treatment of solid tumors. This review will detail some of the recent findings that led to better subtyping and treatment of cancers, some of which were historically refractory. Recent Findings: Advances in molecular biology have recently led to the rapid development of personalized cancer management. Molecular markers and gene signatures allow better risk definition and treatment prediction, thus, avoiding 'wasted toxicity'. Recent understandings in disease pathways are giving new hope to treatment of hard-to-treat cancers such as melanoma, subtypes of nonsmall cell lung cancer and several orphan tumors. Summary: This progress transposed from lab to bedside has made personalized cancer care a reality. In addition, this concept is being integrated into clinical trial designs with the enrolment of molecularly selected patients, hopefully leading to high rates of success. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20120314 Date Completed: 20120619 Latest Revision: 20151119 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1097/CCO.0b013e3283521349 |
| PMID: | 22410457 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1531-703X |
|---|---|
| DOI: | 10.1097/CCO.0b013e3283521349 |